According to the results of a study announced by Brazilian national health officials on Thursday, seeking approval from the federal government, according to the candidate vaccine produced by the Chinese company Sannova, its effective rate against the coronavirus is 78%.
More than 12,000 health workers participated in the study, which found 218 cases of COVID-19, of which about 160 were people who received a placebo instead of the actual vaccine.
Turkish officials said last month that a smaller concomitant study of the same candidate vaccine in the country found that it was more than 90% effective.
The Sao Paulo state government, which has a contract with the vaccine, said it will request emergency approval from the Brazilian Federal Health Regulatory Agency on Friday to start using the vaccine. Governor João Doria plans to launch a vaccination campaign for the state’s 46 million residents on January 25.
The Butantan Institute in Sao Paulo, São Nova’s partner in Brazil, did not disclose data, such as the results by age and gender or the number of asymptomatic volunteers in the sample. Many epidemiologists need these data to assess whether the vaccine is eligible. safety standard.
Officials said the details will be announced after Brazil̵
Gonzalo Vecina, one of the founders of Brazil’s health agency, said that the data released so far is reassuring and sufficient to approve its use in emergency situations.
Vecina told The Associated Press: “In general, we do have enough information to continue to register and use it.” “We need to provide 320 million vaccines to 160 million Brazilians, which is our population over 18 years old. If The federal government does not do this, the state government will do it, but we must do it quickly. We are already behind many countries.”
The health agency said in a statement that it has not yet received all the data on the study.
The researchers reported that the study had no serious side effects.
The United States requires at least 30,000 people to test candidate vaccines to determine safety and effectiveness.
At a time when the spread of the coronavirus in China was minimal, the Sinovac candidate was ready for later testing, so that the company was forced to travel to multiple locations abroad to collect the necessary data.
“Today is a day of hope, a day of life,” Doria said at a press conference. Brazil has caused nearly 200,000 deaths due to the virus.
The governor of Sao Paulo is the opponent of President Jair Bolsonaro, who played down the risk of the pandemic from the beginning and repeatedly questioned the quality of Chinese vaccines.
After Doria announced the news, Brazilian Health Minister Eduardo Pazuello stated at a press conference in Brasilia that the Bolsonaro government would purchase up to 100 million doses of Novartis. vaccine. The Sao Paulo state government confirmed the transaction and initially provided 46 million doses.
Pazulo said: “These shots will be evenly distributed among all states, just like in AstraZeneca.”
The Brazilian Federal Government has reached an agreement to obtain up to 100 million doses of vaccines produced by AstraZeneca, of which 70 million are produced in the family soil.
Pazulo said that the lenses produced by the pharmaceutical companies Pfizer and Modena have proven to be effective, expensive, and bring many legal problems. He also said that the Brazilian government is keen to buy disposable vaccines developed by Jensen, if they work.
In the evening, shortly after Brazil’s official COVID-19 death toll exceeded 200,000, the São Paulo state government stated that it had reached an agreement with the Brazilian Ministry of Health to provide 46 million doses of vaccine. It did not disclose whether it will continue its vaccination campaign on January 25.
Earlier on Thursday, Bolsonaro told supporters in the capital Brasilia that approval of a vaccine for emergency use should not be mandatory without a vaccine named “Novartis”. So far, his government has no national vaccination plan.
Bolsonaro said: “No one can force a person to do something with unclear consequences.” The president had experienced a COVID-19 rebound earlier, but he reiterated that he would not get any vaccines.
Another Chinese company, SinoPharm, announced last week that its similar vaccine is about 79% effective. These vaccines all rely on inactivated viruses.